• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BAYER PHARMA AG ESSURE; TRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BAYER PHARMA AG ESSURE; TRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE Back to Search Results
Model Number ESS305
Device Problems Adverse Event Without Identified Device or Use Problem (2993); Appropriate Term/Code Not Available (3191)
Patient Problem Arthralgia (2355)
Event Type  Injury  
Event Description
The below report was received by health authority ansm (reference number: (b)(4)) on 25-apr-2023.The most recent information was received on 16-may-2023.This spontaneous case was originally reported by a consumer and describes the occurrence of arthralgia ("joint pain") in an adult female patient who had essure inserted (lot no.A27188).Additional non-serious events are detailed below.There was no information on the patient's medical history or concurrent conditions.On (b)(6)2013, the patient had essure inserted.In 2013 she experienced oropharyngeal discomfort ("throat discomfort since using the method due to my thyroid").An unknown time later she experienced arthralgia (seriousness criterion medically important), goitre ("thyroid hypertrophy") and dysgeusia ("metallic taste in my mouth").At the time of the report, the oropharyngeal discomfort and goitre had not resolved.The outcomes for arthralgia and dysgeusia were unknown.The reporter considered goitre to be related to essure administration.No causality assessment was received for essure with regard to dysgeusia, oropharyngeal discomfort or arthralgia.The reporter commented: throat discomfort since using the method due to my thyroid, 10 years with throat discomfort due to my thyroid, we have just found out!! my doctor could not believe it was linked to it.Diagnostic results (normal ranges are provided in parenthesis if available): body weight was reported to be 73 kg.[ultrasound thyroid] on (b)(6)2023: moderate thyroid hypertrophy, greater on the right side, with a slightly inhomogeneous parenchyma overall and hyperemic on color doppler, but without a pejorative circumscribed area.Ti-rads (thyroid imaging reporting and data system) classification 2.Lot number: a27188 manufacture date: 2012-07 expiration date: 2015-07.Quality-safety evaluation of ptc: for essure: unable to confirm complaint.The most recent follow-up information incorporated above includes data received on: 16-may-2023: quality safety evaluation of ptc.Upon medical review, the case was upgraded to serious incident.We received a lot number in this case.A technical investigation will be conducted, including a batch review, and a review of complaint records and other relevant data; should any new and reportable information become available from our investigation, this will be provided in a supplementary report.
 
Manufacturer Narrative
The below report was received by health authority ansm (reference number: (b)(4)) on (b)(6) 2023.The most recent information was received on (b)(6) 2023.This spontaneous case was originally reported by a consumer and describes the occurrence of arthralgia ("joint pain") in an adult female patient who had essure inserted (lot no.A27188).Additional non-serious events are detailed below.There was no information on the patient's medical history or concurrent conditions.On (b)(6) 2013, the patient had essure inserted.In 2013 she experienced oropharyngeal discomfort ("throat discomfort since using the method due to my thyroid").An unknown time later she experienced arthralgia (seriousness criterion medically important), goitre ("thyroid hypertrophy") and dysgeusia ("metallic taste in my mouth").At the time of the report, the oropharyngeal discomfort and goitre had not resolved.The outcomes for arthralgia and dysgeusia were unknown.The reporter considered goitre to be related to essure administration.No causality assessment was received for essure with regard to dysgeusia, oropharyngeal discomfort or arthralgia.The reporter commented: throat discomfort since using the method due to my thyroid, 10 years with throat discomfort due to my thyroid, we have just found out!! my doctor could not believe it was linked to it.Diagnostic results (normal ranges are provided in parenthesis if available): body weight was reported to be 73 kg.[ultrasound thyroid] on (b)(6) 2023: moderate thyroid hypertrophy, greater on the right side, with a slightly inhomogeneous parenchyma overall and hyperemic on color doppler, but without a pejorative circumscribed area.Ti-rads (thyroid imaging reporting and data system) classification 2 lot number: a27188 manufacture date: (b)(6) 2012 expiration date: (b)(6) 2015.Quality-safety evaluation of ptc: for essure: no defect could be confirmed by the manufacturer.All component batches used for manufacturing of this product batch fulfilled the set specifications.Batch documentation did not reveal any deviations during the manufacturing process that could have caused the described complaint reason.Trend analyses of complaints are reviewed regularly, no signal was observed with regard to the reported complaint reason.The risk management file was reviewed and an update was not deemed required.A technical investigation of the complaint sample could not be conducted, as no sample was available.The most recent follow-up information incorporated above includes data received on: (b)(6) 2023: quality safety evaluation of ptc.We received a lot number in this case.A technical investigation was conducted, including a batch review, and a review of complaint records and other relevant data; should any new and reportable information become available from our investigation, this will be provided in a supplementary report.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ESSURE
Type of Device
TRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE
Manufacturer (Section D)
BAYER PHARMA AG
müllerstr. 178
berlin, 13353
GM  13353
Manufacturer (Section G)
BAYER PHARMA AG
müllerstr. 178
berlin, 13353
GM   13353
Manufacturer Contact
k shaw lamberson
100 bayer blvd, p.o. box 915
whippany, nj 
MDR Report Key16961685
MDR Text Key315694326
Report Number2951250-2023-02087
Device Sequence Number1
Product Code HHS
UDI-Device Identifier10888853003051
UDI-Public(01)10888853003051
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
P020014
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Consumer
Reporter Occupation Other
Type of Report Initial,Followup
Report Date 05/30/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received05/19/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date07/01/2015
Device Model NumberESS305
Device Lot NumberA27188
Is the Reporter a Health Professional? No
Date Manufacturer Received05/26/2023
Date Device Manufactured07/01/2012
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient SexFemale
Patient Weight73 KG
-
-